FPIs have largely been sellers in the domestic market over the past few months.

One such miss is Granules India. An initial investment of around Rs 7 lakh (Rs 6,88,550) in the stock seven years ago could have made you a...

We estimate that OmniChem is going to do anywhere from 180-200 crores revenues with an EBITDA of not less than 20 per cent.

The observations will not have any impact and we are very happy with the outcome of the audit, added Prasad.

Goldman Sachs initiated coverage on Coal India with ‘Buy’ rating with a target price of Rs 360.

C Krishna Prasad, Granules CMD, says the profit and the revenues this quarter have been Rs 80 crores, but this year they expect Rs 180-200 ...

After BoJ played party pooper on D-St, experts believe not much steam is left in the market. Earnings season is the biggest trigger for the...

More analysts are getting attracted to this counter because the recent correction has brought down its valuations to reasonably levels.

An ETMarkets.com survey among the brokerages showed most experts expect the benchmark equity indices to move in the 27,000-31,000 range.

Sensex is down about 4,000 points from its record high of 30,025 hit in March, but Calendar 2016 promises to be better for Indian investors.

Drug firm Granules India has received three observations from the USFDA for its Jeedimetla, Hyderabad facility during a recent inspection.

"On 28th January board meeting directors have approved fundraising plans for Rs 250 crore. We are calling for shareholders meeting on 27th ...

Most of the high beta stocks have more than doubled in the past one year, but analysts feel that there is more upside left in the benchmark...

Granules India has improved its performance after its struggles in FY10 and FY13 thanks to better utilisation of its plants.

Mid-sized pharmaceutical company Granules India is eying to achieve Rs 1,000 crore of revenue during the current financial year 2013-14.